These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 22318514)

  • 1. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
    Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
    Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: NICE guidance.
    Ahmad Y; Lip GY
    Heart; 2012 Oct; 98(19):1404-6. PubMed ID: 22698856
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
    Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
    Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran etexilate: future directions in anticoagulant treatment.
    Schulman S; Reilly PA
    Clin Appl Thromb Hemost; 2009; 15 Suppl 1():32S-41S. PubMed ID: 19679590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
    Lip GY; Larsen TB; Skjøth F; Rasmussen LH
    J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients.
    Ellis CR; Kaiser DW
    Vasc Health Risk Manag; 2013; 9():341-52. PubMed ID: 23874100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dabigatran etexilate for thromboembolic prophylaxis in non-valvular atrial fibrillation: the RE-LY study and substudies with commentary.
    Waks JW; Zimetbaum PJ
    Expert Rev Cardiovasc Ther; 2013 Nov; 11(11):1461-71. PubMed ID: 24147516
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dabigatran in clinical practice.
    Nagarakanti R; Ellis CR
    Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel oral anticoagulants--key messages for the angiologist.
    Haas S; Spannagl M; Schellong SM
    Vasa; 2012 May; 41(3):177-91. PubMed ID: 22565619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Namibia becomes first country in Africa to launch dabigatran etexilate for atrial fibrillation.
    Wagenaar P
    Cardiovasc J Afr; 2011; 22(5):283. PubMed ID: 21983957
    [No Abstract]   [Full Text] [Related]  

  • 12. Hemopericardium in a patient treated with dabigatran etexilate.
    Barton CA; McMillian WD; Raza SS; Keller RE
    Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dabigatran eteksilat new anticoagulant for the prevention of stroke in patients with atrial fibrillation without valvular lesions].
    Panchenko EP
    Kardiologiia; 2011; 51(11):83-90. PubMed ID: 22117775
    [No Abstract]   [Full Text] [Related]  

  • 14. Should dabigatran replace warfarin for stroke prevention in AF?
    Drug Ther Bull; 2011 Oct; 49(10):114-7. PubMed ID: 21994438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical considerations in the use of novel oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation.
    Deitelzweig S
    Cardiovasc Ther; 2014 Apr; 32(2):74-81. PubMed ID: 24119252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Old and new oral anticoagulants for venous thromboembolism and atrial fibrillation: a review of the literature.
    Becattini C; Vedovati MC; Agnelli G
    Thromb Res; 2012 Mar; 129(3):392-400. PubMed ID: 22264937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation.
    Huber K; Connolly SJ; Kher A; Christory F; Dan GA; Hatala R; Kiss RG; Meier B; Merkely B; Pieske B; Potpara T; Stępińska J; Klun NV; Vinereanu D; Widimský P
    Int J Clin Pract; 2013 Jun; 67(6):516-26. PubMed ID: 23557519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?
    Escobar C; Barrios V; Jimenez D
    Cardiovasc Ther; 2010 Oct; 28(5):295-301. PubMed ID: 20718760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dabigatran etexilate (Pradaxa) for the treatment of atrial fibrillation.
    Belavic JM
    Nurse Pract; 2011 Sep; 36(9):6-7. PubMed ID: 21857210
    [No Abstract]   [Full Text] [Related]  

  • 20. Rash associated with dabigatran etexilate.
    To K; Reynolds C; Spinler SA
    Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.